Life prolonging effect of antitumor agents on postoperative adjuvant therapy in the lung spontaneous metastasis model in mice

Anticancer Research

Volumn 18, Issue 2 A, 1998, Pages 1203-1209

  Shibata, Jiro ^a   Murakami, Koji ^a   Abe, Masaaki ^a   Hashimoto, Akihiro ^a   Utsugi, Teruhiro ^a   Fukushima, Masakazu ^a   Yamada, Yuji ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antiangiogenesis; Life prolonging effect; Spontaneous metastasis; UFT

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXIFLURIDINE; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; IRINOTECAN; UFT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; LIFESPAN; LUNG METASTASIS; MOUSE; NEPHRECTOMY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; TEGAFUR; URACIL;

EID: 0031864534     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Gandara DR, Crowly J, Livingston RB, Ferez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM, Braun TJ, Natale RB, and Balcerzak SP: Evaluation of cisplatin intensity in metastatic non- small-cell lung cancer: A phase III study of the Southwest Oncology group. J Clin Oncol 11: 873-878, 1993.
2. Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, Woodburn R, Drasga R, Songer J, Fisher W, Stephens D and Hui S: Random prospective study of vindesine versus vindesine plus high-dose cisplatin venus vindesine plus cisplatin plus mitomycin C in advanced non- small-cell lung cancer. J Clin Oncol 4: 1037-1043, 1986.
3. Perng RP, Chen Y-M, Ming-Liu J, Tsai C-M, Lin W-C, Yang K-Y, and Whang-Peng J: Gemicitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 15: 2097-2102, 1997.
4. Francis PA, Rigas JR, Kris MG, Pisters KMW, Orazem JP, Woolley KJ, and Heelan RT: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12: 1232-1237, 1994.
5. Bicknell R and Harris AL: Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis. Cancer Biol 3: 399-407, 1992.
6. Maccubbin DL, Whitman JA, Taniguchi N, Mace KF, Ehrke MJ and Mihich E: Comparison of adriamycin induced immunomodulation with that of 17 the noncardiotoxic anthracycline 5-iminodaunorubicin, Int J Immunopharmac 10: 317-323, 1988.
7. Hayashi H, Nio Y, Kawabata K, Araya S, and Imamura M: Cis-diamminedichloroplatinum(II) augments expression of tumor-associated antigens on human gastric cancer cell line KATO-3 and increases susceptibility and binding of tumor cells to various cytotoxic effector cells. J Surg Oncol 62: 162-170, 1996.
8. Fujii S, Kitano S, Ikenaka K and Shirasaka T: Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives. Jpn. J Cancer Chemother 6: 377-384, 1979.
9. Toide H, Akiyoshi H, Minato Y, Okuda H and Fujii S: Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil, Gann (Jpn J Cancer Res) 6: 553-560, 1977.
10. Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanowski K, Oka M and Saijo N: Synergism between cisplatin and topoisomerase I inhibitor, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 56: 789-793, 1996.
11. Kaneda N, Nagata H, Furuta T and Yokokura T: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715-1720, 1990.
12. Yanase T, Tamura M, Fujita K, Kodama S and Tanaka K: Inhibitory effectof angiogenesis inhibitorTNP-470 on tumorgrowth and metastasis of human cell lines in vitro and in vivo, Cancer Res 53: 2566-2570, 1993.
13. Antoine N, Greimers R, De Roanne C, Kusaka M, Meinen E, Simar LJ and Castronovo V: AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 54: 2073-2076, 1994.
14. Dinney CPN, Bucana CD, Utsugi T, Fidler IJ, Eschenbach AC and Killion JJ: Therapy of spontaneous lung metastasis of murine renal adenocarcinoma by systemic administration of liposomes containing the macrophage activator CGP 31362. Cancer Res 51: 3741-3747, 1991.
15. Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T and Matsumoto K: Antitumor activity of a camptotecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28: 192-198, 1991.
16. Inaba M: Pharmacokinetic approach to the improvement of clinical predictability in the preclinical test for antitumor agents. Jpn J Cancer Chemother 18: 1449-1456, 1991.
17. Inaba M, Kobayashi T, Tashiro T, Sakurai Y, Maruo K, Ohnishi Y, Ueyama Y and Nomura T: Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose. Cancer 64: 1577-1582, 1989.
18. Bossi P, Viale G, Lee AKC, Alfano R, Coggi G and Bosari S: Angiogenesis in colorectal tumors: Microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res 55: 5049-5053, 1995.
19. Utsugi T, Shibata J, Sugimoto Y, Aoyagi K, Wierzba K, Kobunai T, Terada T, Oh-hara T, Tsuruo T and Yamada Y: Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res 56: 2809-2814, 1996.
20. Pazdur R, Lassere Y, Diaz-Canton E, Bready B and Ho DH: Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities. Anticancer Drugs 7: 728-733, 1996.
21. Yamada Y, Toko T, Miyauchi S and Unemi N: Effect of UFT on immune response in mice. Jpn., J Cancer Chemother 7: 2134-2140, 1980.
22. Kubota Y, Hosaka M, Fukushima S and Kondo I: Prophylactic Oral UFT therapy for superficial bladder cancer. Cancer 71: 1842-1845, 1993.
23. Cook AF, Holman MJ, Kramer MJ and Trown PW: Fluorinated pyrimidine nucleosides.3. Synthesis and antitumor activity of a series of 5′- deoxy-5-fluoropyrimidine nucleosides. J Med Chem 22: 1330-1335, 1979.
24. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A and Maruyama HB: Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5- fluorouridine. Gann (Jpn J Cancer Res) 71: 112-123, 1980.
25. Wada H, Hitomi S, Teramatsu T and the West Japan study group for lung cancer surgery: Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 14: 1048-1054, 1996.
26. Suzuki M, Aida I, Ohwada M, Sato I, Tamura T and Kasuga Y: 5-FU concentration in the blood and tumor tissue after 5′-DFUR or UFT administration in the patients with uterine cervical cancer. Jap J Cancer Chemother 22: 253-258, 1995.
27. Miyazaki K, Yakushiji H, Kitahara K, Mori M, Sasatomi E, Tsutsumi N, Hirohashi Y, Iwanaga A, Iyama A, Fukagawa H and Hisatsugu T: A comparative study of the serum and tissue 5-FU concentrations in the patients with hepatocellular carcinoma after preoperative oral administration of UFT and 5′-DFUR. Jap J Cancer Chemother 21: 641-645, 1994.
28. Fukamura T, Umeno T, Jyozaki H, Haruta J, Okamoto K, Hashimoto M, Arima S and Shimura H: Study of tissue drug concentration of fluorinated pyrimidine anticancer drugs -comparison of 5′DFUR and UFT-, 1990. Jap J Cancer Chemother 17: 1887-1892, 1990.
29. Shimizu E, Kimura K, Sone S, Inoue I, Nakamura Y, Noda Y, Hojo F, Yagi M, Nakanishi S, Yamasaki K, Yamashita T and Ogura T: A phase II study of UFT for non-small cell lung cancer. Jpn J Cancer Chemother 13: 2970-2973, 1986.
30. Nio Y, Kimura H, Tsubono M, Tseng C-C, Kawabata K, Masai Y, Hayashi H, Araya S, Meyer C and Fukumoto M: A comparative study of the antitumor activities of 5′-deoxy-5-fluorouridine and its prodrug trimethoxy benzoyl-5′-deoxy-5-fluorouridine (RoO9-1390) on human digestive organ cancer xenograft lines transplanted into nude mice, Anti-Cancer Drugs 3: 387-393, 1992.
31. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y and Ishitsuka H: Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 31: 175-178, 1983.
32. Kurebayashi J, Nukatsuka M, Fujioka A, Saito H, Takeda S, Unemi N, Fukumori H, Kurosumi M, Sonoo H and Dickson RB: , Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice. Clinical Cancer Res 3: 653-659, 1997.
33. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
34. Teicher BA, Sotomayor EA and Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702-6704, 1992.
35. Kato T, Sato K, Kakinuma H and Matsuda Y: Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(Chloroacetyl- carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 54: 5143-51 47, 1994.